Related Experiment Video
Updated: Feb 13, 2026

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells
Published on: May 6, 2013
Carbamazepine, a beta-cell protecting drug, reduces type 1 diabetes incidence in NOD mice
Jason T C Lee1, Iryna Shanina2, Yung Ning Chu1
1Diabetes Research Group, UBC Life Sciences Institute, Department of Cellular and Physiological Sciences, Vancouver, BC, Canada.
Abstract:
Pancreatic beta-cells are selectively destroyed by the host immune system in type 1 diabetes. Thus, drugs that preserve beta-cell mass and/or function have the potential to prevent or slow the progression of this disease. We recently reported that the use-dependent sodium channel blocker, carbamazepine, protects beta-cells from inflammatory cytokines in vitro. Here, we tested the effects of carbamazepine treatment in female non-obese diabetic (NOD) mice by supplementing LabDiet 5053 with 0.5% w/w carbamazepine to achieve serum carbamazepine levels of 14.98 ± 3.19 µM. Remarkably, diabetes incidence over 25 weeks, as determined by fasting blood glucose, was ~50% lower in carbamazepine treated animals. Partial protection from diabetes in carbamazepine-fed NOD mice was also associated with improved glucose tolerance at 6 weeks of age, prior to the onset of diabetes in our colony. Less insulitis was detected in carbamazepine treated NOD mice at 6 weeks of age, but we did not observe differences in CD4+ and CD8+ T cell composition in the pancreatic lymph node, as well as circulating markers of inflammation. Taken together, our results demonstrate that carbamazepine reduces the development of type 1 diabetes in NOD mice by maintaining functional beta-cell mass.
Insights
Carbamazepine, a sodium channel blocker, reduced type 1 diabetes development by approximately 50% in non-obese diabetic mice. This treatment preserved functional pancreatic beta-cell mass, suggesting a potential therapeutic strategy for diabetes prevention.
Area of Science:
- Immunology
- Endocrinology
- Pharmacology
Background:
- Type 1 diabetes involves autoimmune destruction of pancreatic beta-cells.
- Preserving beta-cell mass and function is crucial for preventing or slowing disease progression.
- Carbamazepine, a sodium channel blocker, demonstrated in vitro protection of beta-cells from inflammatory cytokines.
Purpose of the Study:
- To investigate the in vivo efficacy of carbamazepine in preventing type 1 diabetes.
- To assess the impact of carbamazepine on beta-cell mass and function in a mouse model.
Main Methods:
- Female non-obese diabetic (NOD) mice were fed a diet supplemented with carbamazepine (0.5% w/w).
- Serum carbamazepine levels were maintained at approximately 15 µM.
- Diabetes incidence was monitored via fasting blood glucose over 25 weeks.
- Glucose tolerance and insulitis were assessed at 6 weeks of age.
Main Results:
- Carbamazepine treatment reduced diabetes incidence by ~50% in NOD mice.
- Improved glucose tolerance was observed in treated mice prior to diabetes onset.
- Reduced insulitis was detected in carbamazepine-treated mice, indicating less pancreatic inflammation.
Conclusions:
- Carbamazepine effectively reduces the development of type 1 diabetes in NOD mice.
- The drug appears to maintain functional beta-cell mass, contributing to its protective effect.
- Carbamazepine shows promise as a therapeutic agent for type 1 diabetes prevention.
Related Concept Videos
Types of Reports II: Incident or Occurrence Report
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Drug Delivery Systems: Different Types
Antihypertensive Drugs: Action of β1 Blockers

